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Abstract 
1H-MRS variability increases due to normal aging and also as a result of atrophy in grey and white matter 
caused by neurodegeneration. In this work, an automatic process was developed to integrate data from spectra 
and high-resolution anatomical images to quantify metabolites, taking into account tissue partial volumes within 
the voxel of interest avoiding additional spectra acquisitions required for partial volume correction. To evaluate 
this method, we use a cohort of 135 subjects (47 male and 88 female, aged between 57 and 99 years) classified 
into 4 groups: 38 healthy participants, 20 amnesic mild cognitive impairment patients, 22 multi-domain mild 
cognitive impairment patients, and 55 Alzheimer's disease patients. Our findings suggest that knowing the voxel 
composition of white and grey matter and cerebrospinal fluid is necessary to avoid partial volume variations in a 
single-voxel study and to decrease part of the variability found in metabolites quantification, particularly in those 
studies involving elder patients and neurodegenerative diseases. The proposed method facilitates the use of 1H-
MRS techniques in statistical studies in Alzheimer's disease, because it provides more accurate quantitative 
measurements, reduces the inter-subject variability, and improves statistical results when performing group 
comparisons.  
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INTRODUCTION 
Intensive efforts are being made to devise novel treatments to slow the progression of 
Alzheimer’s disease (AD), the most common neurodegenerative form of dementia [1]. Over the past 
fewdecades, researchers have tried to clinically define this grey area of cognitive decline that 
probably represents a transitional state between usual brain aging and dementia [2]. Mild cognitive 
impairment (MCI) has been proposed as a transitional state between healthy aging and AD [3]. 
Although MCI is a category at high risk of developing dementia, namely 10–15% per year compared 
to 1–2% in the healthy elderly population [4], some MCI patients never develop dementia and not 
allADpatients pass through the MCI stage.  
 
Many studies have been performed in order to detect clinical, neuropsychological, and biological 
predictive markers of progression of MCI to AD [2] to assess the differences between MCI and 
normal aging or AD. Brain damage in AD and MCI begins in the medial temporal lobe, including the 
hippocampus, the parahippocampal gyrus, and entorhinal cortex extending to the limbic system [5–
8]. Medial temporal lobe and hippocampal atrophy has been considered as a significant marker of 
dementia in subjects with MCI [9–11].  
 
Proton magnetic resonance spectroscopy (
1
H-MRS) is a useful technique for studying brain 
metabolites in both health and illness [12–14]. 1H-MRS studies provide insight into the in vivo 
metabolism of dementia and in particular AD identifying an evolutionary pattern of regional 
metabolite abnormalities [4]. In AD, the main finding with 1H-MRS is the decreased levels of N-
acetylaspartate (NAA) and the increased levels myo-inositol (mI) in the occipital, temporal, parietal, 
and frontal regions of patients with AD even at the early stages of the disease [15–18].  
 
The NAA is a marker of healthy neuronal density. Consistent with this and with the pathological 
changes known to occur in neurodegenerative dementing illnesses [19], localized 
1
H-MRS has shown 
reduced NAA in different brain regions of AD and MCI patients [4, 15, 20–25]. Dixon and 
colleagues [26] found a significant reduction of the NAA level in the left hippocampus of AD 
patients in 1-year follow-up. Adalsteinsson et al. [27] found that reduction in NAA concentration in 
the grey matter (GM) was more sensitive in detecting cognitive decline in AD than was structural 
GM volume measured with MRI. However, other cross-sectional studies investigating NAA changes 
in MCI compared with cognitively healthy subjects yielded negative findings [28–30].  
 
The role of mI in AD is unclear [2]. Rose and coworkers [31] suggested that its level correlates 
with the progression of the disease and with the number of the neurofibrillary tangles. This 
metabolite is higher in many other neurological diseases, so its specificity is low [27]. Studies 
performed in Down’s syndrome, which frequently evolves in a type of dementia similar to AD, found 
mI levels to be higher compared to controls [32]. There have been reports of increased mI, which is 
suggestive of an increase in glial content or membrane abnormality, in subjects with AD [29, 33–37]. 
Parnetti et al. [37] have reported that the increase of mI correlated with dementia severity and 
duration [12].  
 
Combining these two findings, it has been suggested that mI/NAA ratios may provide a basis for 
a 
1
H-MRS diagnostic assay for AD [35, 38]. The study of Wang et al. [39] reveals that the elevation 
of mI/NAA ratio in the hippocampus is more significant than that in the posterior cingulate area, 
which corresponds to the pathologic procession of AD. They found a significant correlation between 
mI/NAA ratio and cognitive decline.  
 
1
H-MRS is a complex and sensitive technique where different sources of variability may affect 
the acquisition and quality of the spectrum. 
1
H-MRS variability increases due to normal aging and 
also as a result of atrophy in GMand white matter (WM) caused by neurodegeneration. As discussed 
earlier, hippocampus is a key region for study of AD. However, it is technically challenging to study 
by 
1
H-MRS, due to its small size and its proximity to areas of air and bone within the skull, which 
affect the magnetic field homogeneity and result in spectra with low resolution and poor signalto- 
noise ratio or, instead, severe partial volume effects from surrounding tissue [26]. 
1
H-MRS 
techniques use rectangular or cubic voxels, which do not usually correspond with the curved shapes 
of the hippocampus and other brain regions. As such, spectroscopy voxel often includes a 
combination of cerebrospinal fluid (CSF), GM, and WM. Because CSF has no measurable 
1
H-MRS 
metabolites, the presence of a large portion of CSF within the voxel, as could happen by tissue 
atrophy in these diseases, could underestimate the metabolite concentrations. Furthermore, metabolite 
concentrations are different in GM and WM [40, 41]. Wang and Li [42] found significant differences 
in metabolite concentrations in GM and WM in the occipital lobe.  
 
Different strategies have been proposed to overcome partial volume effects by combining 
metabolite concentrations with morphological information of MRI studies. Two studies proposed 
methods for correcting the CSF inclusion within the voxel [43, 44]. Another study proposed an 
analysis of two voxels [42], containing different proportions of the tissues. In the study by Sánchez 
González [45], a method that combines the partial volume correction with the correction of the 
metabolite intensity through the signal without water suppression was proposed. These methods 
involve the acquisition of at least two spectra for each subject for the correction, which is an 
important disadvantage in studies involving dementia and elder people, since it implies increasing the 
acquisition time. Studies by Schuff et al. [46], from 12 AD patients and 17 controls, and Dixon et al. 
[26], from 9 AD patients and 14 controls, showed that the combination of hippocampal volume and 
hippocampal NAA concentration with partial volume correction gave better discrimination of AD 
than did either measurement alone. The study of Westman and colleagues [47], from 30 AD patients 
and 36 control subjects, found that combining MRI and 
1
H-MRS measures resulted in a sensitivity of 
97% and a specificity of 94% compared to using MRI or MRS measures alone. Adding 1H-MRS 
measures to MRI measures resulted in significantly better classification than using MRI measures 
alone and the method showed strong potential for discriminating between AD and controls.  
 
These results suggest that precise composition of GM, WM, and CSF is needed in a single-voxel 
study to accurately quantify the metabolite concentrations, particularly in those studies involving 
elder patients and neurodegenerative diseases. This improvement could solve some of the variability 
found in metabolites quantification and explain part of the discrepancies found in the literature. 
Technical developments to reduce this variability may make 
1
H-MRS a viable biomarker in clinical 
trials for AD [1].  
 
In this work, new post-processing techniques have been developed for combining spectroscopy 
data with anatomical images. These techniques quantify metabolite concentrations taking into 
account tissue components (GM, WM, and CSF) within the voxel of interest. Also, they do not 
require additional spectra acquisitions per subject for doing the metabolite corrections, an important 
issue in dementia studies. The main goal is to reduce de within-subject variability and prove if 
1
H-
MRS could be a useful biomarker for dementia and AD studies.  
MATERIAL AND METHODS  
Subjects  
We use a cohort of 135 subjects (47 male and 88 female) aged between 57 and 99 years. They are 
studied in the Alzheimer Research Unit of the Fundación CIEN-Fundación Reina Sofía. The approval 
from the local ethics committee was obtained for this study and all patients gave informed consent for 
participation.  
 
All participants completed the Mini-Mental State Examination [48] and the Clinical Dementia 
Rating Scale to assess their cognitive function [49]. Diagnostic assessment of the MCI patients was 
performed according to Petersen’s criteria [50]. AD status was determined according to the National 
Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related 
Disorders Association [51] criteria for AD.  
 
The 135 subjects were classified into four groups according to these criteria: 38 healthy 
participants, 20 amnesic MCI patients (aMCI), 22 multi-domain MCI patients (mMCI), and 55 AD 
patients.  
  
Data acquisition  
All MR images and spectroscopic data were acquired with a clinical GE Signa HDx 3.0T scanner 
using a single-channel quadrature head coil. The MRI protocol included a spoiled gradient echo (IR-
SPGR) high-resolution T1 volume (TR/TE/TI/flip angle = 9/4/650 ms/12, matrix = 512×512, FOV= 
24×24 cm, NEX= 1, 158 slices×1.0mm slice thickness). The spectroscopy protocol consisted of three 
Point Resolved Spin Echo (PRESS) acquisitions with TR = 1500 ms and TE = 35 ms: two single-
voxel (SV) with a mean size of 5.5 cm
3
 was prescribed in both hippocampi, and a SV with a mean 
size of 8 cm
3
 was placed in the posterior cingulate.  
Data post-processing  
An automatic process has been developed with MATLAB software [52] to:  
 
1. Perform brain tissue segmentation from highresolution T1 3D volume with SPM8 software 
[53]. SPM software performs a voxel-based approach for tissue segmentation using modified 
versions of the ICBM (The International Consortium for Brain Mapping) Tissue Probabilistic 
Atlases [54].  
 
2. Localize the 1H-MRS voxel into the highresolution 3D anatomic volume. To localize the 1H-
MRS voxel into the anatomic 3D study during the post-process, the following is required: a) 
Anatomical localization: image localization and image orientation information from the 
DICOM files; b) Spectroscopic localization: voxel position, voxel size, and voxel orientation 
and rotation. This information is not included in the DICOM files. Therefore is necessary to 
get it from the raw data generated by the scanner; c) Finally, transform the two volumes to a 
common space for represent them together. This involves moving the spectroscopic voxel to 
the 3D anatomical space where it was prescribed.  
 
3. Determine the tissue composition of the voxel from the segmented high-resolution T1 3D into 
GM, WM, and CSF.  
 
4. Quantify spectra using LCModel software [55]. The main brain metabolites in 
neurodegenerative diseases—creatine (Cr), Cholina (Cho), NAA, and mI—were recorded. To 
define a criterion for rejection of poor quality spectra, the Cramer Rao lower bounds for the Cr 
signal intensity (given as %Standard deviation (SD)-value by the LCModel) were used. Only 
those spectra with an SD <20 were included in the study. In all these spectra the linewidth, 
obtained during the shimming process, was (on average) 9, 8, and 7Hz for left hippocampus 
(LH), right hippocampus (RH), and posterior cingulate (PC), respectively, with no significant 
mean differences between the groups.  
 
5. Modify LCModel quantifications applying the method described below.  
 
The last step proposes the modification of the spectra quantification values according to the 
relative proportion of GM, WM, and CSF in each voxel. The theoretical distribution of the metabolite 
concentration (Mc) in a particular voxel is defined by the equation:  
 
 
𝑃(𝑀𝑐) = 𝑃(𝐺𝑀) ∙ 𝑃(𝑀𝑐|𝐺𝑀) + 𝑃(𝑊𝑀) ∙ 𝑃(𝑀𝑐|𝑊𝑀) + 𝑃(𝐶𝑆𝐹) ∙ 𝑃(𝑀𝑐|𝐶𝑆𝐹) (1) 
 
 
 
 
where P(GM), P(WM), and P(CSF) are, respectively, the proportion of GM, WM, and CSF inside the 
voxel and P(Mc|GM), P(Mc |WM), and P(Mc |CSF) are the probabilities of the metabolite 
concentration given this volume of GM, WM, and CSF.  
 
  
Also, it is known that  
 
 
𝑃(𝐺𝑀) =
𝑉𝐺𝑀
𝑉
 (2) 
  
𝑃(𝑊𝑀) =
𝑉𝑊𝑀
𝑉
 (3) 
  
𝑃(𝐶𝑆𝐹) =
𝑉𝐶𝑆𝐹
𝑉
 (4) 
  
𝑃(𝑀𝑐|𝐺𝑀) =
𝐶𝐺𝑀
𝐶𝐺𝑀 + 𝐶𝑊𝑀 + 𝐶𝐶𝑆𝐹
 (5) 
  
𝑃(𝑀𝑐|𝑊𝑀) =
𝐶𝑊𝑀
𝐶𝐺𝑀 + 𝐶𝑊𝑀 + 𝐶𝐶𝑆𝐹
 (6) 
  
𝑃(𝑀𝑐|𝐶𝑆𝐹) =
𝐶𝐶𝑆𝐹
𝐶𝐺𝑀 + 𝐶𝑊𝑀 + 𝐶𝐶𝑆𝐹
 (7) 
 
 
in which VGM, VWM, and VCSF denote, respectively, the volume of GM, WM, and CSF within the 
voxel, obtained from segmentation on high-resolution T1; V is the total volume of the voxel, sum of 
VGM, VWM, and VCSF; CGM, CWM, and CCSF are, respectively, the contributions of the GM, WM, and 
CSF to the metabolite.  
 
Replacing Equations (2) to (7) in Equation (1), we obtain that the theoretical concentration for a 
given metabolite in a particular voxel can be defined by:  
 
 
𝑃(𝑀𝑐) =
𝑉𝐺𝑀
𝑉
∙
𝐶𝐺𝑀
𝐶𝐺𝑀 + 𝐶𝑊𝑀 + 𝐶𝐶𝑆𝐹
  
  
+
𝑉𝑊𝑀
𝑉
∙
𝐶𝑊𝑀
𝐶𝐺𝑀 + 𝐶𝑊𝑀 + 𝐶𝐶𝑆𝐹
  
  
+
𝑉𝐶𝑆𝐹
𝑉
∙
𝐶𝐶𝑆𝐹
𝐶𝐺𝑀 + 𝐶𝑊𝑀 + 𝐶𝐶𝑆𝐹
 (8) 
 
 
However, due to the fact that metabolites only have negligible concentrations in CSF [40, 42], 
CCSF is assumed to be zero and Equation (8) can be rewritten as follows:  
 
 
𝑃(𝑀𝑐) =
𝑉𝐺𝑀
𝑉
∙
𝐶𝐺𝑀
𝐶𝐺𝑀 + 𝐶𝑊𝑀
+
𝑉𝑊𝑀
𝑉
∙
𝐶𝑊𝑀
𝐶𝐺𝑀 + 𝐶𝑊𝑀
 (9) 
 
 
Normal metabolite ratios published by [56] were used to obtain the contribution of GM and WM 
to the quantity of each metabolite. Finally, we combine the theoretic concentration with the LCModel 
result (LCC) as follows:  
 
 
𝑊𝑐 = 𝐿𝐶𝑐 ∙ 𝑃(𝑀𝑐) (10) 
 
 
  
This method obtains a weighted measure (WC) that corrects the quantified concentration by the 
theoretical amount of metabolite for a particular voxel. WC is a metabolite concentration 
measurement corrected for the theoretical expected ratio of metabolite and the volume atrophy within 
the voxel. Furthermore, the proposed method avoids the acquisition of more spectra for each subject, 
which would increase the time and cost of the acquisition.  
Statistical analysis  
Statistical analysis and graphics were performed with PASW Statistics 18.0 (Predictive Analytics 
Soft- Ware). In order to explain differences on metabolite concentration between groups, a 
generalized linear model (GLM) was fitted. Group differences were assessed by means of ANOVA 
and post-hoc test (by the GLM) were performed when ANOVA result was significant.  
 
Statistical significance was set at p < 0.05. Etasquared values (η2) were calculated as a measure of 
effect size. The power of a statistical test is the probability that the test will reject the null hypothesis 
when the null hypothesis is actually false. The ideal power level should be at least 0.8; that is the 
minimum level required for a quantitative research by Cohen in a scale from 0 to 1 [57]. Power 
analysis can be used to calculate the minimum sample size required so that one can be reasonably 
likely to detect an effect of a given size. The effect size is a measure of the strength of the 
relationship between two variables. According to Cohen again, effect size levels are small ∼0.01, 
medium ∼0.06 and large ∼0.14. Statistical power and effect size measures complements test of 
significance such as p-values.  
RESULTS  
Figure 1 displays the typical single-voxel spectroscopy prescription in the right hippocampus 
from one subject, registered onto a high-resolution T1- weighted image (Fig. 1a–c). The resulting 
spectrum (Fig. 1d) exhibits four distinctive peaks, these being (from right to left)NAA, Cr, Cho, and 
mI. In this figure, LCModel spectral fit is shown in black (thick line) and raw data in grey (thin line). 
Figure 2 illustrates the segmented GM volume (Fig. 2a), WM volume (Fig. 2b), and CSF volume 
(Fig. 2c) from high resolution T1 of Fig. 1. Right hippocampus SV is registered onto the three 
volumes (GM, WM, and CSF) to obtain the partial volumes within the voxel. Figure 3 shows the 
boxplots with the partial volume distributions on the SV placed at both hippocampi and the posterior 
cingulate along the different groups: Fig. 3a – the ratio VGM/V, Fig. 3b – the ratio VWM/V, and Fig. 3c 
– the ratio VCSF/V.  
 
 
 
Fig. 1. Single voxel prescription in the right hippocampus from one subject, registered onto a high-resolution T1 SPGR: 
sagittal (a), transverse (b), and coronal (c) view. Resulting LCModel spectrum (d). 
  
 
 
 
Fig. 2. SPM8 brain tissue segmentation from high-resolution T1 SPGR from Fig. 1: GM (a), WM (b), and CSF (c) in sagittal, 
transverse and coronal view. Single voxel at right hippocampus registered onto the three volumes. 
 
 
 
Fig. 3. Boxplots for the partial volume distributions within the voxel: (a) VGM/V, (b) VWM/V, and (c) VCSF/V in each group for 
left hippocampus (LH) SV, right hippocampus (RH) SV, and Posterior Cingulate (PC) SV. 
  
Main brain metabolites concentrations were evaluated for each group. Mean values of mI (dark-
colored) and NAA (light-colored) concentrations for both absolute and corrected measurements are 
shown in Fig. 4. Figure 4a and d show the values for left hippocampus SV, Fig. 4b and e show the 
values for right hippocampus SV, and Fig. 4c and f shows the values for posterior cingulate SV. Top 
row (Fig. 4a–c) shows the mI and NAA concentrations along different groups. Bottom row (Fig. 4d–
f) shows the mI and NAA weighted concentrations after applying the proposed method for metabolite 
concentration correction.  
 
 
 
Fig. 4. Mean values of mI (dark-colored) and NAA (light-colored) concentration along different groups for (a, d) left 
hippocampus (left column), (b, e) right hippocampus (middle column), and (c, f) posterior cingulate (right column). Top row 
(a, b, c) shows LCModel results (LCc) and bottom row (c, d, f) shows the results corrected by the proposed method (Wc). 
Figure 5 shows the variance of mI and NAA concentration in different groups for both LCModel 
metabolite concentration (dotted line) and weighted by atrophy within the voxel (solid line). Figure 
5a shows the results for left hippocampus, Fig. 5b shows the results for right hippocampus, and Fig. 
5c shows the results for posterior cingulate.  
 
 
 
Fig. 5. Variance of mI (dark-colored) and NAA (light-colored) concentration along different groups for (a) LH (b) RH, and (c) 
PC. Figures show the variances for absolute LCModel metabolite concentration (dotted line, LCc in figure legend) and for 
weighted concentration correction (solid line, Wc in figure legend). 
  
Table 1 shows the results of the statistical analysis for those metabolite concentrations and ratios 
which means resulted significantly differences in ANOVA, say mI, NAA, Cho, mI/Cr, and mI/NAA, 
in both hippocampi and the posterior cingulate. First row shows the p-values for ANOVA analysis. 
Also, it shows the p-values, the statistical power, and the effect size estimates for two-group mean 
differences (Control-aMCI, Control-mMCI, and Control-AD comparisons). For each variable, the 
first column shows the results for LCModel absolute concentrations and the second column shows 
the results for corrected values.  
Table 1. Statistical test for group mean differences of mI, NAA, Cho, mI/Cr, and mI/NAA. For each SV location (LH and 
RH): p-values for ANOVA analysis (first row), p-values for mean differences with Control group, statistical power, and effect 
size (η2) statistics for LCModel concentration (first column, LCC) and weighted by partial volume. Test of significance was 
calculated for p < 0.05 
p-values mI  NAA  Cho  mI/Cr  mI/NAA 
  LCC WC  LCC WC  LCC WC  LCC WC  LCC WC 
                
LH  ANOVA 0.102 0.026  0.001 0.000  0.000 0.000  0.002 0.000  0.000 0.000 
 
Control–
aMCI 
0.041 0.006  0.311 0.038  0.669 0.168  0.044 0.019  0.016 0.006 
 
Control–
mMCI 
0.664 0.142  0.000 0.000  0.000 0.000  0.001 0.000  0.000 0.000 
 
Control–
AD 
0.317 0.030  0.000 0.000  0.001 0.000  0.000 0.000  0.000 0.000 
 
Statistical 
Power∗ 
0.528 0.698  0.997 0.999  0.981 0.997  0.981 0.973  0.991 0.999 
 η2∗ 0.050 0.068  0.191 0.245  0.154 0.194  0.153 0.147  0.172 0.246 
RH  ANOVA 0.045 0.015  0.021 0.000  0.003 0.000  0.001 0.000  0.000 0.000 
 
Control–
aMCI 
0.963 0.610  0.220 0.107  0.280 0.265  0.900 0.490  0.308 0.126 
 
Control–
mMCI 
0.155 0.027  0.029 0.001  0.032 0.002  0.010 0.005  0.000 0.000 
 
Control–
AD 
0.026 0.002  0.019 0.001  0.000 0.000  0.000 0.002  0.000 0.000 
 
Statistical 
Power∗ 
0.654 0.817  0.713 0.993  0.900 0.969  0.927 0.868  0.993 0.979 
 η2∗ 0.073 0.100  0.089 0.137  0.126 0.160  0.182 0.115  0.199 0.170 
PC  ANOVA 0.002 0.003  0.000 0.000  0.144 0.398  0.000 0.000  0.000 0.000 
 
Control–
aMCI 
0.321 0.341  0.116 0.688  0.100 0.109  0.277 0.358  0.709 0.538 
 
Control–
mMCI 
0.110 0.025  0.316 0.031  0.290 0.224  0.025 0.009  0.049 0.120 
 
Control–
AD 
0.000 0.000  0.102 0.000  0.028 0.004  0.000 0.000  0.000 0.000 
 
Statistical 
Power∗ 
0.915 0.992  0.752 0.978  0.467 0.531  0.975 0.998  0.988 0.999 
 η2∗ 0.112 0.172  0.077 0.148  0.043 0.049  0.146 0.199  0.163 0.230 
                
 
DISCUSSION  
The voxel partial volume analysis shown in Fig. 3 reveals a loss of GM and WM with the 
progression of the disease in both hippocampi and to a lesser extent in the posterior cingulate. This 
fact is accompanied by an increase of CSF within the voxel. As shown in Fig. 3, the posterior 
cingulate is less affected by atrophy.  
 
There is also an increased intra-group variability of the voxel volume distributions with the 
progression of the disease. From the large variations observed in the voxel tissues volumes among 
different groups, it is clear that for inter-subject studies, metabolite concentration correction should 
be considered to avoid partial volume effects between tissue types because this may lead to 
misinterpretations. Control and aMCI groups does not show important differences in voxel partial 
volumes, therefore differences in metabolites concentration shall not be due to atrophy. Results for 
absolute metabolite concentrations show a decrease of NAA concentration and an increase of mI 
concentration with the progression of the disease in both hippocampi (Fig. 4a, b). These results agree 
with earlier studies reported in the literature [4, 15, 20–25, 29, 33–37]. Figure 4c and f show this 
trend is attenuated in the posterior cingulate with little variations in mI and NAA levels among 
groups for both absolute and corrected metabolite quantifications. This agrees with the low atrophy 
found in the posterior cingulate and more stability among groups. Regarding hippocampi metabolite 
concentrations corrected by the proposed method, Fig. 4d and e show how the same trend is kept for 
the ratio mI/NAA at within-group level in hippocampi. Also, the behavior of NAA continues in the 
same line as for LCModel concentrations, decreasing with the progression of the disease. However, 
mI behavior changes. The method proposed in Equation (10) obtains a weighted measure that 
corrects the absolute concentration by the theoretical expected ratio of metabolite concentration and 
volume atrophy within the voxel. Thus, as the tissue atrophy should increase with the progression of 
the disease, the metabolite concentration should be smaller for less volume of tissue (ratios VGM/V 
and VwM/V in Equation (9) are smaller). Therefore, the reason why mI decreases along groups for 
corrected measures is that the atrophy is taking into account, but, as mentioned above, the ratio 
mI/NAA is kept, following the well-known behavior across groups.  
 
Furthermore, the most important results from this work are regarding the variance of the 
metabolite concentrations. Figure 5 shows how AD group has the largest variability in both 
hippocampi and the posterior cingulate. From Fig. 5a and b, it is shown that Control and MCI groups 
present more irregularities in their variability depending on the hemisphere, meaning metabolite 
quantification could potentially be different depending on the hemisphere. Also, it is shown that mI 
has higher variability than NAA. Figure 5a and b also shows an increase of the within-group 
variability with the progression of the disease for the absolute measures in both hippocampi. Results 
in the posterior cingulate (Fig. 5c) are a slightly different. mI and NAA has similar variability across 
groups, being lower than in hippocampi. AD group has the largest variability like in hippocampi, but 
it is noteworthy that MCI groups have lower variability than Controls. By applying the correction on 
the absolute measures, the same trend continues for the hippocampi and posterior cingulate, but the 
within-group variability is significantly reduced. With this method, the trend of the mean remains 
between metabolites within the groups, but the variance is considerably decreased. This fact justifies 
the use of methods for correction by the partial volumes due to some of the variability found in the 
quantification could be explained by the partial volume effect within the voxel.   
 
The variability reduction can also be demonstrated mathematically. Using Equation (10), the 
variance with the proposed method can be defined as:  
 
 
𝑉𝑎𝑟[𝑊𝑐] = 𝑉𝑎𝑟[𝐿𝐶𝑐 ∙ 𝑃(𝑀𝑐)] (11) 
 
 
Being P(Mc) a constant, Equation (11) can be rewritten as:  
 
 
𝑉𝑎𝑟[𝑊𝑐] = 𝑃(𝑀𝑐) 
2𝑉𝑎𝑟[𝐿𝐶𝑐] ≤ 𝑉𝑎𝑟[𝐿𝐶𝑐] (12) 
 
 
Equation (12) shows how the variance of the proposed method is always less than or equal to the 
variance of LCModel concentrations, being P(Mc)
2
 < 1.  
 
From the results of statistical hypothesis tests shown in Table 1, highlight the following points:  
 
1. Best statistical results were observed in left hippocampus, with significant differences between 
Control and aMCI groups. This result complies well with the neuropathologic concept of 
evolution of AD according to the Braak staging [58]. Atrophy typically starts in the medial 
temporal lobe and limbic areas, subsequently spreading to parietal association areas, and 
finally to frontal and primary cortices. First damage in AD is observed in the left temporal 
lobe. Generally, major changes in MCI and AD appear on the left hemisphere.  
 
2. While no significant results were found in LCModel concentration of mI, statistical test with 
corrected measures revealed significant differences between controls and aMCI andADgroups 
in left hippocampus and between controls and mMCI and AD groups in right hippocampus.  
 
3. mI/Cr and mI/NAA ratios were the best markers to differentiate control group from aMCI, 
mMCI, and AD groups with meaningful values of statistical power and effect size. In contrast 
to studies [4] and [2], no significant differences were found in NAA/Cr in this study. Also, 
statistical test for NAA concentration did not improve too much with corrected values.  
 
4. Statistical significance, statistical power, and effect size values improved when metabolite 
concentrations were corrected, mainly for mI/NAA ratio in left hippocampus, getting values of 
0.99 and higher than 0.2 in power and effect size respectively and p < 0.0001.  
 
5. Despite suitable results obtained for the ratio mI/NAA, different behavior is observed in mI, 
NAA, mI/Cr, and NAA/Cr before and after doing correction. This could be due to whatwas 
already reported by Zhu [59], where no significant correlations were found in this study 
between these two metabolites. These results suggest a disassociation between mI and NAA 
alterations in AD, changes occur in the same brain regions but not at the same time or rate. 
According to Zhu, there would be a dependency of the staging of the disease.  
 
 
Figure 1 shows ‘non-hippocampus’ volume included in the spectroscopic voxel. Trying to reduce 
the voxel size resulted in poor shim and poor line width adjustment and spectra with very low 
resolution and poor signal-to-noise ratio. Hence, the importance of the proposed method, allowing a 
larger voxel while the variability is reduced and increases the ANOVA statistical power. It should be 
also noted that using ‘non-hippocampus’ normal metabolite ratios [56] for correct metabolite 
concentrations might not be the most optimal choice. However, these values are used as a relative 
measure of what we consider a measure of normality, like a surrogate of metabolite concentration. 
Since the goal is to differentiate among groups, the reference used does not matter too much as long 
as the same concentration for controls and patients was used and, unfortunately, we did not found any 
publication reporting normal hippocampal concentrations.  
 
In this work, an automatic process was developed for integrate data from spectra and high-
resolution anatomical images to quantify metabolite concentrations taking into account tissue partial 
volumes within the voxel of interest avoiding specific GM and WM SV spectra acquisition required 
for partial volume correction. This process facilitates the use of 
1
H-MRS techniques in statistical 
studies in AD, because the modification of metabolites concentrations by the voxel tissue 
composition: (1) provides more accurate quantitative measurements, (2) reduces the inter-subject 
variability, and (3) improves the statistical results when performing group comparisons in studies of 
normal aging and neurodegenerative diseases. Specifically, mI/NAA ratio has been shown to be a 
robust and sensitive marker to differentiate between subject groups.  
 
These findings suggest that knowing the voxel composition of WM, GM, and CSF is necessary to 
avoid partial volume variations in a single-voxel study and to decrease part of the variability found in 
metabolites quantification, particularly in those studies involving elder patients and 
neurodegenerative diseases. Also, the improvement of the statistical power and effect size means a 
reduction in the sample size, which suggests a potential for important cost savings. 
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